TG Therapeutics Sees Unusually High Options Volume (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the target of some unusual options trading activity on Monday. Investors bought 13,927 call options on the company. This is an increase of 105% compared to the typical volume of 6,778 call options.

TG Therapeutics Price Performance

NASDAQ TGTX traded up $4.33 during trading hours on Monday, reaching $34.42. The company's stock had a trading volume of 13,494,362 shares, compared to its average volume of 2,441,278. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $5.36 billion, a price-to-earnings ratio of -344.17 and a beta of 2.26. The firm's 50-day moving average price is $30.79 and its 200-day moving average price is $28.24.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.06. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, equities research analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now owns 670,632 shares of the company's stock, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.50% of the stock is owned by corporate insiders.

Institutional Trading of TG Therapeutics

Hedge funds have recently bought and sold shares of the stock. Bleakley Financial Group LLC purchased a new position in shares of TG Therapeutics during the fourth quarter valued at about $245,000. Castellan Group purchased a new position in TG Therapeutics during the 4th quarter valued at approximately $8,539,000. Oppenheimer & Co. Inc. purchased a new position in TG Therapeutics during the 3rd quarter valued at approximately $759,000. Segall Bryant & Hamill LLC bought a new stake in TG Therapeutics in the 3rd quarter worth approximately $1,225,000. Finally, Barclays PLC raised its holdings in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after acquiring an additional 158,323 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on TGTX shares. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday, November 25th. StockNews.com lowered shares of TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. Finally, The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.